Effects of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) by Composite Physiologic Index (CPI)

被引：0
作者：
Nambiar, A. M. [1 ]
Molina-Molina, M. [2 ]
Padilla, M. [3 ]
Song, J. [4 ]
Mueller, H. [5 ]
Stowasser, S. [5 ]
Rohr, K. B. [5 ]
Wells, A. U. [6 ,7 ]
机构：
[1] Univ Texas Hlth San Antonio, Div Pulm & Crit Care Med, Dept Med, San Antonio, TX USA
[2] Univ Hosp Bellvitge, ILD Unit, IDIBELL, Barcelona, Spain
[3] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Pulm & Crit Care Med, Seoul, South Korea
[5] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[6] Royal Brompton & Harefield NHS Fdn Trust, Natl Inst Hlth Res, Resp Biomed Res Unit, London, England
[7] Imperial Coll, Natl Heart & Lung Inst, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1905
引用
收藏
页数：2
相关论文
共 50 条
  • [31] HEALTHCARE RESOURCE UTILIZATION AND RELATED COSTS IN PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (ILDS)
    Olson, A.
    Hartmann, N.
    Patnaik, P.
    Garry, E.
    Bohn, R.
    Singer, D.
    Baldwin, M.
    Wallace, L.
    [J]. VALUE IN HEALTH, 2020, 23 : S353 - S353
  • [32] Does HRCT pattern influence the effect of nintedanib in patients with progressive fibrosing interstitial lung diseases?
    Behr, J.
    Brown, K. K.
    Walsh, S. L. F.
    Devaraj, A.
    Song, J. W.
    Wuyts, W. A.
    Valenzuela, C.
    Goeldner, R. G.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    [J]. PNEUMOLOGIE, 2021, 75 : S31 - S32
  • [33] EFFECTS OF NINTEDANIB ON CIRCULATING BIOMARKERS IN PATIENTS WITH PROGRESSIVE FIBROSING AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES
    Maher, T.
    Bonella, F.
    Assassi, S.
    Noth, I.
    Diefenbach, C.
    Ittrich, C.
    Rohr, K.
    Kolb, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 722 - 722
  • [34] Does HRCT Pattern Influence the Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases?
    Brown, K. K.
    Walsh, S. L. F.
    Devaraj, A.
    Song, J.
    Wuyts, W. A.
    Valenzuela, C.
    Goeldner, R.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [35] Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial
    Inoue, Yoshikazu
    Wells, Athol U.
    Song, Jin Woo
    Xu, Zuojun
    Kitamura, Hideya
    Suda, Takafumi
    Okamoto, Masaki
    Mueller, Heiko
    Coeck, Carl
    Rohr, Klaus B.
    Kolb, Martin
    Brown, Kevin K.
    [J]. RESPIROLOGY, 2023, 28 (05) : 465 - 474
  • [36] Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analyses from the INBUILD Trial
    Kolb, M. R.
    Flaherty, K. R.
    Silva, R. S.
    Prasse, A.
    Patel, N. M.
    Vancheri, C.
    Quaresma, M.
    Goeldner, R.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [37] Nintedanib in children and adolescents with fibrosing interstitial lung diseases
    Deterding, Robin
    Young, Lisa R.
    DeBoer, Emily M.
    Warburton, David
    Cunningham, Steven
    Schwerk, Nicolaus
    Flaherty, Kevin R.
    Brown, Kevin K.
    Dumistracel, Mihaela
    Erhardt, Elvira
    Bertulis, Julia
    Gahlemann, Martina
    Stowasser, Susanne
    Griese, Matthias
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (02)
  • [38] Effects of nintedanib on dyspnoe, cough and quality of life in patients with progressive fibrosing interstitial lung diseases: findings from the INBUILD trial
    Kreuter, M.
    Swigris, J. J.
    Richeldi, L.
    Wijsenbeek, M.
    Nunes, H.
    Suda, T.
    James, A.
    Rohr, K. B.
    Quaresma, M.
    Flaherty, K. R.
    [J]. PNEUMOLOGIE, 2021, 75 : S24 - S24
  • [39] Effects of Nintedanib on Dyspnea, Cough and Quality of Life in Patients with Progressive Fibrosing Interstitial Lung Diseases: Findings from the INBUILD Trial
    Swigris, J. J.
    Richeldi, L.
    Wijsenbeek, M.
    Kreuter, M.
    Nunes, H.
    Suda, T.
    James, A.
    Rohr, K. B.
    Quaresma, M.
    Flaherty, K. R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [40] Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial
    Koschel, D.
    Flaherty, K. R.
    Wells, A. U.
    Cottin, V
    Devaraj, A.
    Inoue, Y.
    Richeldi, L.
    Walsh, S. L. F.
    Kolb, M.
    Moua, T.
    Stowasser, S.
    Goeldner, R. G.
    Schlenker-Herceg, R.
    Brown, K. K.
    [J]. PNEUMOLOGIE, 2021, 75 : S30 - S31
12345